# Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)

> **NCT00431041** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 132 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** solifenacin
- **DRUG:** oxybutynin immediate release

## Key facts

- **NCT ID:** NCT00431041
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2010-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431041, "Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00431041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*